Role of VHL gene mutation in human cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The von Hippel-Lindau (VHL) tumor suppressor gene is crucial in hereditary cancer syndromes and sporadic tumors.
• The VHL protein (pVHL) regulates the oxygen-sensing pathway by targeting hypoxia-inducible factor (HIF) for degradation.
• HIF stabilization in the absence of pVHL promotes angiogenesis and cell survival, contributing to tumor formation.

Purpose of the Study:

• To elucidate the role of the VHL-HIF interaction in tumor development.
• To explore potential therapeutic strategies targeting HIF or its downstream effectors for VHL-related cancers.

Main Methods:

• Analysis of VHL gene mutations in hereditary and sporadic cancers.
• Investigation of pVHL's mechanism in regulating HIF stability via prolyl hydroxylation.
• Assessment of HIF's role in pVHL-defective tumor formation.

Main Results:

• Germline VHL inactivation leads to VHL disease; somatic mutations are found in hemangioblastomas and renal cell carcinomas.
• pVHL controls HIF levels through oxygen-dependent ubiquitination, mediated by EGLN enzymes.
• HIF stabilization is implicated in pVHL-deficient tumor growth, suggesting HIF as a therapeutic target.

Conclusions:

• The VHL-HIF pathway is central to oxygen sensing and tumor suppression.
• Targeting HIF or vascular endothelial growth factor (VEGF) may offer new treatments for VHL-related cancers.
• Emerging genotype-phenotype correlations suggest pVHL may have functions beyond HIF regulation.